Zymeworks Stock (NYSE:ZYME)
Previous Close
$11.00
52W Range
$7.97 - $17.70
50D Avg
$12.71
200D Avg
$12.69
Market Cap
$761.17M
Avg Vol (3M)
$622.49K
Beta
1.17
Div Yield
-
ZYME Company Profile
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; BeiGene, Ltd.; and Exelixis, Inc. It also has licensing and research collaboration with LEO Pharma A/S to research, develop, and commercialize bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada.
ZYME Performance
Peer Comparison
| Ticker | Company |
|---|---|
| MRSN | Mersana Therapeutics, Inc. |
| YMAB | Y-mAbs Therapeutics, Inc. |
| RVMD | Revolution Medicines, Inc. |
| TERN | Terns Pharmaceuticals, Inc. |
| BLUE | bluebird bio, Inc. |
| ZNTL | Zentalis Pharmaceuticals, Inc. |
| EDIT | Editas Medicine, Inc. |
| APLS | Apellis Pharmaceuticals, Inc. |
| RLAY | Relay Therapeutics, Inc. |
| ALEC | Alector, Inc. |
| STOK | Stoke Therapeutics, Inc. |
| PRQR | ProQR Therapeutics N.V. |
| ARWR | Arrowhead Pharmaceuticals, Inc. |
| DAWN | Day One Biopharmaceuticals, Inc. |
| ANNX | Annexon, Inc. |
| TVTX | Travere Therapeutics, Inc. |
| CABA | Cabaletta Bio, Inc. |
| SNDX | Syndax Pharmaceuticals, Inc. |
| BPMC | Blueprint Medicines Corporation |
| AKRO | Akero Therapeutics, Inc. |
| CYTK | Cytokinetics, Incorporated |
| PTGX | Protagonist Therapeutics, Inc. |
| INZY | Inozyme Pharma, Inc. |